Ocean Biomedical Statistics
Share Statistics
Ocean Biomedical has 34.82M shares outstanding. The number of shares has increased by 2.19% in one year.
| Shares Outstanding | 34.82M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 10.38M |
| Failed to Deliver (FTD) Shares | 166 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 165.46K, so 0.48% of the outstanding shares have been sold short.
| Short Interest | 165.46K |
| Short % of Shares Out | 0.48% |
| Short % of Float | 1.59% |
| Short Ratio (days to cover) | 2.64 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.83.
| PE Ratio | 0 |
| Forward PE | -0.83 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ocean Biomedical Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07, with a Debt / Equity ratio of -0.13.
| Current Ratio | 0.07 |
| Quick Ratio | 0.07 |
| Debt / Equity | -0.13 |
| Total Debt / Capitalization | -15.41 |
| Cash Flow / Debt | -0.78 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is null% and return on capital (ROIC) is 3.16%.
| Return on Equity (ROE) | null% |
| Return on Assets (ROA) | null% |
| Return on Capital (ROIC) | 3.16% |
| Revenue Per Employee | 0 |
| Profits Per Employee | 62.83K |
| Employee Count | 9 |
| Asset Turnover | null |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 7.64% in the last 52 weeks. The beta is 1.53, so Ocean Biomedical 's price volatility has been higher than the market average.
| Beta | 1.53 |
| 52-Week Price Change | 7.64% |
| 50-Day Moving Average | 0.7 |
| 200-Day Moving Average | 1.18 |
| Relative Strength Index (RSI) | 46.47 |
| Average Volume (20 Days) | 239.60K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -2.48M |
| Net Income | 565.47K |
| EBITDA | -957.74K |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
The company has 4.00K in cash and 12.12M in debt, giving a net cash position of -12.11M.
| Cash & Cash Equivalents | 4.00K |
| Total Debt | 12.12M |
| Net Cash | -12.11M |
| Retained Earnings | -196.06M |
| Total Assets | 1.85M |
| Working Capital | -29.46M |
Cash Flow
In the last 12 months, operating cash flow was -9.43M and capital expenditures 0, giving a free cash flow of -9.43M.
| Operating Cash Flow | -9.43M |
| Capital Expenditures | 0 |
| Free Cash Flow | -9.43M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OCEA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.84% |
| FCF Yield | -43.68% |
Analyst Forecast
Currently there are no analyst rating for OCEA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -176.27 |
| Piotroski F-Score | 1 |